(Q38020941)

27 August 2017

title

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes (English)

1 reference

27 August 2017

1 reference

Eduard Montanya

1

0 references

language of work or name

English

0 references

publication date

1 July 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1451-1467

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

How hypoglycaemia can affect the life of a person with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Impaired regulation of the incretin effect in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Mild renal impairment and the efficacy and safety of liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Acute pancreatitis associated with liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide-associated acute pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.692777

10.1517/14656566.2012.692777

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference